Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.88
    +0.07 (+0.08%)
     

  • GOLD FUTURES

    2,330.30
    -8.10 (-0.35%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,491.51
    -1,826.61 (-3.43%)
     

  • CMC Crypto 200

    1,388.81
    -35.29 (-2.48%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

BUZZ-Regulus Therapeutics: Strategic Partner reduces stake

Reuters - UK Focus

** Regulus shares down about 7 pct premarket as strategic partner AstraZeneca (NYSE: AZN - news) reduces its holdings.

** AstraZeneca files intent to sell unregistered 2m shares, $20.47 indicative price, through market maker Morgan Stanley (Xetra: 885836 - news) .

** Sources cite Morgan Stanley priced shares at $18.25, vs. Wednesday's $19.62 last sale.

** AstraZeneca acquired 6.25m shares in private placement alongside company's Oct 2012 IPO, at $4 public offering price.

** Offering represents about 4 pct of shares outstanding.

** Stock continues steep ascent, up 200 pct in a month, after hepatitis C drug (HCV) test results showed promise and company reported earnings.

** Drug developer raised about $70 mln last month in public offering which saw founding company Isis Pharmaceuticals (Stuttgart: 881866 - news) monetize portion of its stake. (RM (LSE: RM.L - news) : lance.tupper.thomsonreuters.com@reuters.net)